91 related articles for article (PubMed ID: 23498720)
1. Role of MYCN in retinoblastoma.
Felsher DW
Lancet Oncol; 2013 Apr; 14(4):270-1. PubMed ID: 23498720
[No Abstract] [Full Text] [Related]
2. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
Maris JM
Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
[No Abstract] [Full Text] [Related]
3. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
4. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.
Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D
J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337
[TBL] [Abstract][Full Text] [Related]
5. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
6. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
7. Genomic differences between retinoma and retinoblastoma.
Sampieri K; Mencarelli MA; Epistolato MC; Toti P; Lazzi S; Bruttini M; De Francesco S; Longo I; Meloni I; Mari F; Acquaviva A; Hadjistilianou T; Renieri A; Ariani F
Acta Oncol; 2008; 47(8):1483-92. PubMed ID: 18785023
[TBL] [Abstract][Full Text] [Related]
8. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome.
van Bokhoven H; Celli J; van Reeuwijk J; Rinne T; Glaudemans B; van Beusekom E; Rieu P; Newbury-Ecob RA; Chiang C; Brunner HG
Nat Genet; 2005 May; 37(5):465-7. PubMed ID: 15821734
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
10. MYCN in neuronal tumours.
Schwab M
Cancer Lett; 2004 Feb; 204(2):179-87. PubMed ID: 15013217
[TBL] [Abstract][Full Text] [Related]
11. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
[TBL] [Abstract][Full Text] [Related]
12. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
13. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
14. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
[No Abstract] [Full Text] [Related]
15. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
16. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
17. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
[TBL] [Abstract][Full Text] [Related]
19. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
20. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
